Clinical Trial Update: Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating concurrent durvalumab with radiotherapy for Stage III Non-Small Cell Lung Cancer has completed and results were posted on 2025-03-21…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Non Small Cell Lung Cancer, Lung Cancer Stage III | Phase 2 | Status: COMPLETED | Results posted: 2025-03-21